John Rondoni Sells 58 Shares of Inspire Medical Systems, Inc. (NYSE:INSP) Stock

Inspire Medical Systems, Inc. (NYSE:INSP) CTO John Rondoni sold 58 shares of Inspire Medical Systems stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $215.00, for a total value of $12,470.00. Following the sale, the chief technology officer now directly owns 11,322 shares of the company’s stock, valued at approximately $2,434,230. This represents a 0.51 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Inspire Medical Systems Price Performance

Shares of NYSE:INSP opened at $203.03 on Friday. Inspire Medical Systems, Inc. has a 1 year low of $123.00 and a 1 year high of $257.40. The firm has a market capitalization of $6.08 billion, a PE ratio of 189.75 and a beta of 1.32. The business’s 50 day moving average price is $191.71 and its 200-day moving average price is $183.69.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, November 4th. The company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.54. The business had revenue of $203.20 million during the quarter, compared to analyst estimates of $197.59 million. Inspire Medical Systems had a net margin of 4.37% and a return on equity of 5.30%. The company’s revenue for the quarter was up 32.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.29) earnings per share. As a group, analysts expect that Inspire Medical Systems, Inc. will post 1.33 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Inspire Medical Systems by 1.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 7,879 shares of the company’s stock valued at $1,461,000 after purchasing an additional 79 shares during the last quarter. Diversified Trust Co increased its stake in shares of Inspire Medical Systems by 3.8% in the 4th quarter. Diversified Trust Co now owns 4,686 shares of the company’s stock worth $869,000 after acquiring an additional 173 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of Inspire Medical Systems by 3,812.6% during the 3rd quarter. Principal Financial Group Inc. now owns 141,089 shares of the company’s stock worth $29,777,000 after acquiring an additional 137,483 shares during the period. Oddo BHF Asset Management Sas acquired a new position in shares of Inspire Medical Systems during the 3rd quarter valued at about $1,208,000. Finally, Synovus Financial Corp grew its holdings in shares of Inspire Medical Systems by 7.5% in the third quarter. Synovus Financial Corp now owns 3,502 shares of the company’s stock valued at $739,000 after purchasing an additional 244 shares during the period. 94.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on INSP shares. Truist Financial restated a “buy” rating and issued a $240.00 price objective (up from $217.00) on shares of Inspire Medical Systems in a research note on Monday, September 30th. Wells Fargo & Company upped their target price on Inspire Medical Systems from $187.00 to $198.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Robert W. Baird boosted their price target on Inspire Medical Systems from $240.00 to $252.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Stifel Nicolaus reaffirmed a “hold” rating and set a $200.00 price objective (up previously from $170.00) on shares of Inspire Medical Systems in a research note on Tuesday, November 5th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $260.00 target price (up from $255.00) on shares of Inspire Medical Systems in a research note on Tuesday, November 5th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $233.58.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.